CONMED Corporation (CNMD) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, CNMD scores 65 out of 100, a letter grade of C, labeled "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

• Fundamental Cash Engine: 13 / 20. Per the RQD rating, this reflects ROIC of 7.8% and an FCF yield of 11.07%. Per the market data, ROIC is 7.8% and FCF yield is 11.07%. The FCF yield is the strongest cash-generation datapoint in the set, but ROIC at 7.8% is a modest return on invested capital.
• Whale / 13F Flow: 10 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The holder section contains no 13F detail, so the specific drivers of this score cannot be verified from the source data. It is the weakest pillar.
• Insider Conviction: 15 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The source data contains no transaction-level insider records, so the score cannot be traced to individual trades.
• Macro Regime Fit: 13 / 20. Per the RQD rating, this reflects Beta of 1.0 and sector sensitivity. A beta of 1.0 indicates market-level volatility relative to the broader market.
• Forensic Balance Sheet: 14 / 20. Per the RQD rating, this reflects Altman Z of 1.91, Piotroski F of 7/9, and Debt/Equity of 0.5. These are mid-range readings; the Altman Z sits below the 3.0 level commonly cited as a safe zone, though that threshold is not stated in the source data.

For a prospective investor, the rating points to a balanced setup rather than a clear directional call. Upside drivers in the data include the high FCF yield, a Piotroski score of 7/9, and a forward P/E (26.9) below trailing P/E (28.9), which implies expected earnings growth. Valuation tradeoffs are material: trailing P/E of 28.9 and EV/EBITDA of 11.4 are elevated relative to the 7.8% ROIC. The price of 45.72 sits within a 52-week range of $31.44 to $53.66. The rating does not constitute a recommendation.

CONMED Corporation (CNMD) is listed on the NYSE in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry, per the company profile. The source data does not describe its specific products, customers, or revenue model. Gross margin of 54.6% per the market data indicates a high-margin product mix, but the source data does not identify how those products reach end markets or how the company makes money beyond these financial figures.

The news wire contains six items, all tagged to CNMD, with headlines and summaries that are generic in nature:

• Yahoo Finance item on Q3 earnings key metrics (YELLOW, MARKET WIRE).
• TradingView item reporting a 12-month price target raised to $46.83, implying 2% upside (GREEN, CATALYST).
• Seeking Alpha item on the 2026 Q3 earnings call presentation dated 2026-11-01 (YELLOW, MARKET WIRE).
• Simply Wall St stock analysis item (YELLOW, MARKET WIRE).
• Yahoo Finance stock forecasts item (YELLOW, MARKET WIRE).
• Stock Titan item reporting sales fell 0.7%, but grew 6.7% after currency shifts and exited product lines were excluded (YELLOW, MARKET WIRE).

The most concrete catalyst is the Stock Titan item, which distinguishes reported sales decline from an adjusted growth figure. The price target item is the only one that carries a quantitative figure in its headline. The Butterfly Supply-Chain Graph lists no links and no proprietary signals, so it adds no cross-company catalyst information. Risk watch items include the gap between reported and adjusted sales growth noted in the Stock Titan headline, and the reported decline in FY 2025 net income.

Per the Butterfly Supply-Chain Graph, supply chain status is "NONE," with no butterfly links and no proprietary signals. The source data therefore contains no upstream or downstream dependency mapping, no sector correlation data beyond the sector and industry labels, and no identified 2nd-order bottlenecks. Investors should treat supply-chain exposure as unverified from this dataset.

• What drove the decline in net income from $132.4M in FY 2024 to $47.1M in FY 2025, and how much of it reflects the exited product lines noted in the news wire?
• What are the reported EPS, cash, and debt figures for each fiscal year, since the financial table shows these as unavailable?
• What are the institutional 13F holdings and the specific insider Form 4 transactions behind the whale and insider pillar scores?
• What analyst consensus rating and price target distribution underlie the single price target figure cited in the news wire?
• Which products and end markets generate the 54.6% gross margin, and how much of revenue comes from each?